Gossamer Bio (NASDAQ:GOSS) Cut to “Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Gossamer Bio (NASDAQ:GOSS) from a hold rating to a sell rating in a research report report published on Friday morning.

Several other research firms have also recently issued reports on GOSS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Gossamer Bio in a report on Wednesday, October 8th. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Gossamer Bio in a research note on Thursday. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $8.50.

Gossamer Bio Stock Performance

Shares of GOSS opened at $2.70 on Friday. Gossamer Bio has a one year low of $0.76 and a one year high of $3.87. The stock has a 50-day moving average price of $3.10 and a 200 day moving average price of $2.61. The company has a market capitalization of $624.94 million, a P/E ratio of -3.91 and a beta of 1.92.

Gossamer Bio (NASDAQ:GOSS) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.02). The business had revenue of $13.29 million for the quarter, compared to analysts’ expectations of $6.32 million. Gossamer Bio had a negative return on equity of 1,774.72% and a negative net margin of 354.50%. As a group, equities research analysts forecast that Gossamer Bio will post -0.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of GOSS. Ciovacco Capital Management LLC bought a new stake in shares of Gossamer Bio during the 3rd quarter valued at about $27,000. NorthCrest Asset Manangement LLC acquired a new position in Gossamer Bio in the fourth quarter valued at approximately $36,000. Brighton Jones LLC bought a new position in shares of Gossamer Bio during the third quarter valued at approximately $36,000. Brevan Howard Capital Management LP acquired a new stake in shares of Gossamer Bio during the 3rd quarter worth approximately $37,000. Finally, Mercer Global Advisors Inc. ADV bought a new stake in shares of Gossamer Bio in the 3rd quarter worth approximately $41,000. 81.23% of the stock is owned by institutional investors and hedge funds.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.